Nixpan 40 IV Injection

Nixpan 40 IV Injection 
Pantoprazole Sodium 40 mg/vial

Category:

Indications
Nixpan is indicated where suppression of acid secretion has therapeutic benefit; i.e Peptic ulcer diseases

  • Gastroesophageal reflux diseases
  • Ulcer induced by non-steroidal anti-inflammatory drugs (NSAIDs)
  • Eradication of Helicobacter pylori (in combination with antibiotics)
  • Zollinger-Ellison Syndrome

Pharmacology
Pantoprazole is a proton pump inhibitor that suppresses the final step in gastric acid production by covalently binding to the H+/K+ATPase enzyme system at the surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus that persists longer than 24 hours.

Dosage & Administration
Duodenal ulcer and gastric ulcer: 40 mg once daily for 7-10 days

  • Gastroesophageal reflux disease associated with a history of erosive esophagitis: 40 mg once daily for 7-10 days
  • Prevention of rebleeding in peptic ulcer: IV 80 mg, followed by 8 mg/hour infusion for 72 hours
  • Prophylaxis of acid aspiration: 80 mg IV every 12 h for 24 h, followed by 40mg every 12 hour
  • Long-term management of Zollinger-Ellison Syndrome and other pathological hypersecretory conditions: 80 mg IV every 12 hours, may increase to 80 mg every 8 hours if needed, may titrate to higher doses depending on acid output.

Interaction
No significant drug interactions have been observed in clinical studies.

Contraindications
Pantoprazole is contraindicated in patients with known hypersensitivity to any of the components of the formulation.

Side Effects
Nixpan is well tolerated in both short-term and long-term treatment. Headache and diarrhea are the common side effects and rarely included side effects are abdominal pain, flatulence, rash, insomnia and hyperglycemia.

Precautions & Warnings
Patients should be cautioned that Nixpan tablet should not be split, chewed or crushed. Long-term therapy of Nixpan may lead to malabsorption of cyanocobalamin (Vitamin B12) or may increase the risk of osteoporosis related disorders.

Pregnancy & Lactation
US FDA Pregnancy Category of Pantoprazole is B. There are, however, no adequate and well-controlled studies in pregnant woman. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Pantoprazole has been shown to be excreted in human milk. So, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the benefit of the drug to the mother.

Overdose Effects
There are no known symptoms of overdosage in humans. Since Nixpan is highly protein bound, it is not readily dialyzable. Apart from symptomatic and supportive management, no specific therapy is recommended.

Therapeutic Class
Proton Pump Inhibitor

Storage Conditions
Keep in a dry place, away from light and heat. Keep out of the reach of children.

Nixpan 40 IV Injection
Scroll to top